Neurogene Newsroom

Neurogene Price Target Raised to $72.00/Share From $45.00 by Leerink Partners

Dow JonesNov 12 22:40

Neurogene (NGNE) Receives a Buy From Stifel Nicolaus

TipRanksNov 12 22:19

Baird Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $72

Futu NewsNov 12 20:34

TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating

Futu NewsNov 12 20:31

Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and Neurogene (NGNE)

TipRanksNov 12 20:26

Neurogene Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 12 19:57

HC Wainwright & Co. Maintains Buy on Neurogene, Raises Price Target to $55

BenzingaNov 12 19:48

Neurogene Analyst Ratings

BenzingaNov 12 19:47

William Blair Sticks to Its Buy Rating for Neurogene (NGNE)

TipRanksNov 12 18:38

William Blair Maintains Neurogene(NGNE.US) With Buy Rating

Futu NewsNov 12 18:37

William Blair Maintains Neurogene(NGNE.US) With Buy Rating

Futu NewsOct 22 17:33

BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65

Futu NewsOct 16 19:34

BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65

Futu NewsAug 14 22:32

BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65

Futu NewsAug 14 19:36

Buy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial Outlook

TipRanksAug 14 19:27

Buy Rating Affirmed for Neurogene Amid Promising Outlook for Gene Therapy Candidate NGN-401

TipRanksAug 13 21:57

Buy Rating for Neurogene Based on Strong Clinical Prospects and Technological Advantages

TipRanksAug 12 18:37

Neurogene Analyst Ratings

BenzingaAug 12 18:37

Buy Rating Affirmed for Neurogene Amid Promising Clinical Trials and Strategic FDA Milestones

TipRanksAug 9 22:09

Neurogene Secures RMAT Designation and Joins FDA START Program, Analyst Maintains Buy Rating

TipRanksAug 9 19:07